Ranasinghe R, Mathai M, Zulli A. Revisiting the therapeutic potential of tocotrienol. BioFactors. 2022;48(4):813–56. https://doi.org/10.1002/biof.1873
In Figure 5, it was originally labeled that tocotrienol downregulates NF‐kB inhibition. The correct label is “upregulates NF‐kB inhibition”. The corrected Figure 5 is shown below. We apologize for this error.
FIGURE 5.
Anticancer effects of tocotrienol compared with docetaxel. MCP‐1—monocyte chemo‐attractant protein‐1; MAPK—mitogen‐activated protein kinase pathway; NF‐kB—nuclear factor kappa beta pathway; LPS—lipopolysaccharide; M1 and M2—the two broad divisions of macrophage types; SCC—squamous cell carcinoma. Straight arrows indicate stimulation/upregulation and dotted arrows represent downregulation/inhibition mechanisms.